Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double blind, placebo-controlled, dose-escalating, multiple-dose Phase 2 study of BLX-1002 in type 2 diabetes mellitus
2006-002852-13Phase 2Completed
- Sponsor
- Bexel Pharmaceuticals
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BLX-1002 in type 2 diabetes mellitus (T2DM) and hypertriglyceridemia (3 arms), sponsored by Bexel Pharmaceuticals. Primary endpoints: Pharmacodynamic effects on blood glucose profile, Pharmacodynamic effects on triglycerides and 2 more. Started Jun 2006; status: completed.
02
Drugs
BLX-1002
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemia
Beyond the preview
Go deeper on 2006-002852-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002852-13.